KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Boston Scientific (BSX) Restructuring Costs (2016 - 2026)

Boston Scientific's Restructuring Costs history spans 18 years, with the latest figure at $3.0 million for Q1 2026.

  • On a quarterly basis, Restructuring Costs fell 70.0% to $3.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was $94.0 million, a 1242.86% increase, with the full-year FY2025 number at $101.0 million, changed N/A from a year prior.
  • Restructuring Costs hit $3.0 million in Q1 2026 for Boston Scientific, down from $16.0 million in the prior quarter.
  • Over the last five years, Restructuring Costs for BSX hit a ceiling of $131.0 million in Q4 2022 and a floor of -$111.0 million in Q3 2023.
  • Historically, Restructuring Costs has averaged $13.7 million across 5 years, with a median of $8.0 million in 2024.
  • The widest YoY moves for Restructuring Costs: up 8200.0% in 2025, down 200.0% in 2025.
  • Tracing BSX's Restructuring Costs over 5 years: stood at $131.0 million in 2022, then tumbled by 184.73% to -$111.0 million in 2023, then skyrocketed by 89.19% to -$12.0 million in 2024, then surged by 233.33% to $16.0 million in 2025, then crashed by 81.25% to $3.0 million in 2026.
  • Business Quant data shows Restructuring Costs for BSX at $3.0 million in Q1 2026, $16.0 million in Q4 2025, and -$8.0 million in Q3 2025.